


# Public private partnership



This graphic above shows connections between the Gates Foundation, Wellcome Trust, WHO, GAVI and other NGOs and Big Pharma... It contains round about 6500 objects including like Persons, NGOs, Companies, Documents, etc. It also includes more than 7200 links between them.

All information is publicly available.

The following slides presents some selected organizations from this graphic. Cause of the complexity it shows mostly only the first level of connection.

First, you will get some general information about people from government agencies, companies and non-governmental organizations, as well as some important events or groups. Further on in this document you will find a link analysis of these "stakeholders".


The red lines are always payments, but there might be also some black lines are payments as well. Please see link description.

**Please make your own opinion and do your own research!**


2021-09-12

YGL -  
Young  
Global  
Leaders

BMGF -  
Bill & Melinda  
Gates  
Foundation



# Grants from BMGF, Wellcome Trust and OP



# Total Grants by Bill & Melinda Gates Foundation (1994-2021) - Top 50 Rows

3	Sum of AMOUNT COMMITTED
4	GRANTEE COUNTRY
5	United States
6	Switzerland
7	United Kingdom
8	India
9	Kenya
10	Nigeria
11	Canada
12	South Africa
13	Pakistan
14	Germany
15	France
16	Netherlands
17	Mexico
18	China
19	Australia
20	Korea, Republic of
21	Belgium
22	Japan
23	Italy
24	Saudi Arabia
25	Philippines
26	Bangladesh
27	Congo
28	Norway
29	Côte d'Ivoire
30	Uganda
31	Peru
32	Spain
33	Tanzania, United Republic of
34	Ethiopia
35	Indonesia
36	United Arab Emirates
37	Senegal
38	Singapore
39	Ghana
40	Denmark
41	Thailand
42	Colombia
43	Finland
44	Malaysia
45	Zimbabwe
46	Brazil
47	Viet Nam
48	Sweden
49	Turkey
50	Poland
51	Lithuania
52	Zambia
53	Mauritius
54	Burkina Faso
55	
56	Israel
57	Latvia
58	Chile
59	Rwanda

3	Row Labels	Sum of AMOUNT COMMITTED
4	GAVI Alliance	4.949.056.550,00
5	World Health Organization	3.382.840.574,00
6	The Global Fund to Fight AIDS, Tuberculosis and Malaria	2.998.391.281,00
7	PATH	2.578.300.627,00
8	University of Washington Foundation	1.376.710.904,00
9	United Negro College Fund, Inc.	1.338.312.107,00
10	The Rotary Foundation of Rotary International	1.285.286.700,00
11	United States Fund for UNICEF	1.143.667.405,00
12	The GAVI Campaign	1.137.924.663,00
13	International Bank for Reconstruction and Development	1.126.822.007,00
14	Johns Hopkins University	742.059.691,00
15	MMV Medicines for Malaria Venture	726.814.710,00
16	Alliance for a Green Revolution in Africa	638.359.987,00
17	Clinton Health Access Initiative Inc	544.166.541,00
18	Aeras	513.993.536,00
19	Foundation for the National Institutes of Health (FNIH)	504.887.034,00
20	Global Alliance for TB Drug Development Inc	476.021.941,00
21	New Venture Fund	419.530.642,00
22	Hispanic Scholarship Fund	419.110.327,00
23	International AIDS Vaccine Initiative (IAVI)	412.901.894,00
24	CARE	410.167.727,00
25	Emory University	387.854.910,00
26	UNICEF Headquarters	382.653.424,00
27	United Nations Foundation	363.530.983,00
28	Centro Internacional de Mejoramiento de Maiz y Trigo	360.843.458,00
29	Population Services International	352.941.086,00
30	PATH Vaccine Solutions	343.795.819,00
31	Duke University	326.168.706,00
32	World Health Organization Nigeria Country Office	319.456.633,00
33	University of Manitoba	315.966.351,00
34	London School of Hygiene and Tropical Medicine	305.031.150,00
35	Imperial College London	303.563.584,00
36	Harvard University	298.632.120,00
37	University of Washington	281.914.723,00
38	University of California San Francisco	280.217.094,00
39	Gates Medical Research Institute	276.968.362,00
40	Family Health International	266.536.106,00
41	Cornell University	259.876.471,00
42	International Food Policy Research Institute	256.163.096,00
43	University of Oxford	254.033.626,00
44	Islamic Development Bank	246.108.304,00
45	University of Maryland, Baltimore	245.788.209,00
46	Save the Children Federation, Inc.	244.266.744,00
47	International Vaccine Institute	242.583.242,00
48	World Health Organization Pakistan Country Office	242.356.566,00
49	Columbia University	240.570.937,00
50	The One Campaign	237.469.429,00
51	Global Alliance for Improved Nutrition	235.688.678,00
52	Fred Hutchinson Cancer Research Center	230.704.021,00
53	Cambridge University Development Office in the United States Inc (CUDOUS)	229.449.000,00
54	JSI Research & Training Institute, Inc.	219.074.687,00
55	FHI Solutions LLC	217.951.412,00
56	The Carter Center	215.818.664,00
57	International Development Association	199.732.953,00
58		198.240.210,00

3	Row Labels	Sum of AMOUNT COMMITTED
4	Global Development	21.314.936.294,00
5	Global Health	18.397.247.482,00
6	U.S. Program	9.159.238.029,00
7	Global Growth & Opportunity	7.567.844.633,00
8	Global Policy and Advocacy	4.705.588.960,00
9	Global Development Global Health	2.952.537.749,00
10	Executive	1.626.410.176,00
11	Executive U.S. Program	1.276.629.387,00
12	Global Development Global Policy and Advocacy	827.940.424,00
13	Global Development Global Health Global Policy and Advocacy	520.217.014,00
14	Global Development Global Growth & Opportunity	431.529.680,00
15	Communications Global Development Global Health Global Policy and Advocacy	311.630.758,00
16	Finance and Resource Planning Global Development	308.296.430,00
17	Finance and Resource Planning	264.503.250,00
18	Gender Equality	263.558.725,00
19	Global Policy and Advocacy U.S. Program	238.618.319,00
20	Global Growth & Opportunity Global Policy and Advocacy	157.803.334,00
21	Global Development Global Growth & Opportunity Global Health	147.910.332,00
22	Global Health Global Policy and Advocacy	111.391.622,00
23	Gender Equality Global Development Global Growth & Opportunity Global Health Global Policy and Advocacy	96.408.608,00
24	Gender Equality Global Development	91.754.347,00
25	Foundation Strategy Office	83.796.745,00
26	Gender Equality Global Development Global Health Global Policy and Advocacy	80.929.595,00
27	Global Development Global Growth & Opportunity Global Health Global Policy and Advocacy	74.211.934,00
28	Global Growth & Opportunity Global Health	60.644.183,00
29	Executive Global Health	52.524.087,00
30	Gender Equality Global Growth & Opportunity Global Policy and Advocacy	27.220.184,00
31	Global Development Global Growth & Opportunity Global Policy and Advocacy	25.933.179,00
32	Finance and Resource Planning Global Growth & Opportunity	25.000.000,00
33	Foundation Strategy Office Global Development Global Health	24.140.000,00
34	Gender Equality Global Growth & Opportunity	15.434.354,00
35	Gender Equality Global Policy and Advocacy	11.471.796,00
36	Executive Global Development	10.479.708,00
37	Executive Gender Equality Global Development	10.287.499,00
38	Executive Global Development Global Growth & Opportunity	10.000.000,00
39	Communications Global Policy and Advocacy	8.847.821,00
40	Foundation Strategy Office Global Development Global Growth & Opportunity Global Health Global Policy and Advocacy	8.074.000,00
41	Foundation Strategy Office Global Development	7.581.352,00
42	Executive Global Development Global Growth & Opportunity Global Policy and Advocacy	6.998.115,00
43	Executive Global Policy and Advocacy	6.625.000,00
44	Executive Gender Equality	6.202.113,00
45	Gender Equality Global Development Global Health	5.684.278,00
46	Gender Equality Global Development Global Policy and Advocacy	5.595.280,00
47	Communications	5.449.165,00
48	Gender Equality Global Development Global Growth & Opportunity	4.817.705,00
49	Executive Global Growth & Opportunity	3.500.013,00
50	Global Growth & Opportunity Global Health Global Policy and Advocacy	2.099.891,00
51	Global Health U.S. Program	1.925.000,00
52	Gender Equality Global Development Global Growth & Opportunity Global Health	1.115.582,00
53	Global Growth & Opportunity U.S. Program	733.477,00
54	Foundation Strategy Office Gender Equality	569.234,00
55	Gender Equality Global Health	566.176,00
56	Communications Global Development	199.754,00
57	Foundation Strategy Office Global Health	187.672,00
58	Executive Global Development Global Health	153.208,00

by Devison | By Organization | **by Country** | B

by Devison | **By Organization** | BMGF Grants 2021-09-12 | +


**by Devison** | By Organization | BMGF Grants 2021-09-12 | +

## Overview

Bill & Melinda Gates Foundation, Wellcome Trust, Rockefeller Foundation, World Economic Forum	6
GAVI, CEPI, COVAX, Find, The Global Fund	12
Direct Grants to Swiss Agency for Therapeutic Products, Charite, RKI - Robert Koch Institut, MHRA – Medicines & Healthcare products regulatory Agency and European Commission	23
Direct Grants to World Bank Group and KFW (Link Analysis)	28
Some “Public Websites”	33
Link Analysis	48
Link Analysis – Selected Views	81
IT	96
“EXERCISES”	99
“Meetings”	113
“Gang”	116
Sample of Public Private Partnership - Open Letter to Biden Administration – 3rd August 2021	125
Media	132
Misc	136
“Selected Person”	139

# Bill & Melinda Gates Foundation (BMGF)

Direct connections (extract of entire link analysis)



Details you'll find in separate file: CorinaNetwork\_GatesFoundationOnlyDirectConnections\_2021-09-12.png

[https://en.wikipedia.org/wiki/Bill %26 Melinda Gates Foundation](https://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation)

<https://www.gatesfoundation.org/>

<https://www.gatesfoundation.org/about/financials>









<https://www.gatesfoundation.org/about/committed-grants>











<https://www.gatesfoundation.org/philanthropypartners>











<https://www.gatesfoundation.org/goalkeepers/>

# Bill & Melinda Gates Foundation Strategic Investment FUND

## Portfolio (extract):


	<b>1mg Technologies Private Limited</b> 1mg Technologies Private Limited is a digital consumer healthcare platform in India that provides online-to-offline services to help customers access medicines, diagnostics, and tele-consultations. The foundation invested in the Company to accelerate low-cost delivery of high-quality essential medicines and other <a href="#">Read More</a>
	<b>Abbott Laboratories</b> Abbott Laboratories received support from the foundation to make its Panbio COVID-19 Ag Rapid Test available to low- and middle-income countries. Making high-quality, affordable rapid diagnostic tests with results available in 15-20 minutes is critical in the fight to control <a href="#">Read More</a>
	<b>Achaogen</b> Achaogen is focused on R&D and commercialization of antibacterials to combat multi-drug resistant, Gram-negative infections. The foundation's investment is supporting the development of Achaogen's monoclonal antibody (mAb) discovery platform. <a href="#">Press Release</a>
	<b>Acrobatiq</b> The foundation invested in Acrobatiq, a leader in adaptive learning solutions, to support the growth of a next-generation adaptive learning, courseware, and analytics program. <a href="#">Press Release</a>
	<b>Adjuvant Global Health Technology Fund</b> The foundation has committed to further support the Global Health Investment Fund model by investing as an anchor LP in Adjuvant. Adjuvant is a private investment fund focused on late-stage life sciences investments to address global health challenges. The Fund invests <a href="#">Read More</a>
	<b>Affinivax</b> Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing for multiple antigens to be effectively incorporated in a single vaccine. <a href="#">News Story</a>
	<b>Africa Health Fund</b> The foundation invested in the Africa Health Fund to provide capital to support new approaches to improving the quality and accessibility of private healthcare across the continent.
	<b>African Agricultural Capital Fund</b> The African Agricultural Capital Fund provides growth capital to companies that boost the productivity and profitability of smallholder farmers in East Africa. <a href="#">Press Release</a>
	<b>African Leadership Fund</b> The African Leadership Foundation is a U.S. 501(c)(3) organization with a mission to educate Africa's next generation of young leaders. The foundation provided a loan to support the organization's 2020-2021 school year objectives. Investment Date: May 2020
	<b>AgBiome</b> AgBiome is focused on discovery and development of biological and transgenic products for crop protection. AgBiome identifies microbes from a wide variety of sources to harness their natural abilities to help crops resist pests and stresses. <a href="#">Press Release</a>

	<b>BioE</b> Pharmaceutical company Biological E identifies innovative approaches to reduce the cost of vaccine production. <a href="#">Press Release</a> <a href="#">News Story</a>
	<b>BioNTech</b> BioNTech is focused on combining ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and other serious diseases. The Foundation is working with BioNTech on developing preclinical vaccines and immunotherapy candidates to prevent HIV and tuberculosis infection as <a href="#">Read More</a> <a href="#">Press Release</a>
	<b>bKash</b> Through its mobile payments platform, bKash helps to ensure access to a broader range of financial services for the people of Bangladesh. <a href="#">Press Release</a> <a href="#">News Story</a>
	<b>BloomBoard</b> Software development company BloomBoard received funding from the foundation to help efforts in improving teachers' instructional practices. <a href="#">Press Release</a>
	<b>Butterfly Network</b> Butterfly has created the world's first handheld whole body ultrasound system to democratize healthcare and provide global access to medical imaging. The device is critical to the foundation's vision of an ecosystem where hardware, software, data and expertise come together <a href="#">Read More</a> <a href="#">Press Release</a> <a href="#">News Story</a>
	<b>CHAI (Clinton Health Access Initiative)</b> The foundation provided a guarantee to CHAI to structure volume guarantees to reduce the price and increase access to life-saving commodities in the developing world.
	<b>Charter School Growth Fund Facility Fund</b> The Charter School Growth Fund provides strategic support to high-performing charter management organizations. Inclusive within its support, CSGF provided subordinated bridge loans to address the short-term financing gap CMOs face during construction.
	<b>Charter School Growth Fund Facility Fund III</b> As a follow-on to the CSGF Facility Fund, the organization created a new fund in 2016, to broaden their lending to include early-stage operators, provide more proactive technical assistance and partner with other key stakeholders to remove barriers to affordable charter facilities and financing.
	<b>Civic Builders</b> Funding from the foundation and New Markets Tax Credits, alongside support from Civic Builders, built new schools in a bankrupt city where facilities assistance was otherwise unavailable. <a href="#">Case Study</a>
	<b>ClinVet</b> ClinVet specializes in conducting clinical trials to understand and improve veterinary health products. With the help of the foundation, ClinVet was able to construct a new facility in Morocco to expand its capabilities to conduct trials for livestock products.

	<b>LumiraDx</b> LumiraDx develops point-of-care diagnostics solutions on a portable, cloud-connected reader using finger-prick blood samples tested on disposable, microfluidic strips. The company is working to achieve lab-quality performance and health-IT integration at point-of-care settings globally. The foundation invested in the company <a href="#">Read More</a>
	<b>Lyndra Therapeutics</b> Lyndra Therapeutics is developing an orally administered dosage form designed to deliver sustained, steady-state release of one or more drugs for up to a week or longer while temporarily residing in the stomach. The foundation invested in the company to <a href="#">Read More</a> <a href="#">Press Release</a>
	<b>M-KOPA</b> M-KOPA is a Nairobi-based, off-grid solar energy company which makes residential power systems affordable and accessible to low-income, off-grid customers through a mobile payment-based lease-to-own model. <a href="#">Press Release</a> <a href="#">Case Study</a>
	<b>Medical Credit Fund (MCF)</b> The Medical Credit Fund provides loans and technical assistance to small primary care clinics in Africa. Through the loan fund, MCF expanded its lending and technical assistance across Ghana, Nigeria, Kenya, and Tanzania. <a href="#">Press Release</a>
	<b>Merck</b> The foundation partnered with private and public organizations make Implanon NXT®, a single rod, long-acting, reversible contraceptive implant, available in the world's poorest countries at a more than 50 percent price reduction. <a href="#">Press Release</a> <a href="#">Case Study</a>
	<b>Mylan Dolutegravir</b> Mylan Laboratories, along with Aurobindo Pharma, received support from the foundation to expand the distribution of a single-pill HIV treatment containing dolutegravir to low- and middle-income populations at a low price. <a href="#">Press Release</a> <a href="#">News Story</a>
	<b>OraSure</b> The foundation invested in OraSure to secure a reduced price for the saliva-based HIV self-test OraQuick. <a href="#">Press Release</a> <a href="#">News Story</a>
	<b>Owl Ventures</b> Owl Ventures is a venture investment fund that leads Series A/B investments in US K-12 education technology companies.
	<b>PAHO</b> The Pan American Health Organization (PAHO) is an international public health agency working to improve health and living standards in America.
	<b>Pfizer</b> The foundation invested in Pfizer to expand access to the pharmaceutical company's all-in-one injectable contraceptive, Sayana, giving women in the developing world an affordable option.

# Wellcome Trust

## Direct connections (extract of entire link analysis)




<https://wellcome.org>

[https://en.wikipedia.org/wiki/Wellcome\\_Trust](https://en.wikipedia.org/wiki/Wellcome_Trust)



# Rockefeller Foundation

Here you can see only a small excerpt of the Rockefeller Foundation. The Rockefeller Foundation's connections are actually much more far-reaching. No connections to other Rockefeller Philanthropy Advisors, Rockefeller Brothers Fund, etc. are shown here.



- <https://www.rockefellerfoundation.org/about-us/board-of-trustees/>
- <https://www.rockefellerfoundation.org/grants/>
- [https://en.wikipedia.org/wiki/Rockefeller\\_Foundation](https://en.wikipedia.org/wiki/Rockefeller_Foundation)
- <http://www.nommeraadio.ee/meedia/pdf/RRS/Rockefeller%20Foundation.pdf>

## “The World Economic Forum

*The World Economic Forum is the International Organization for Public-Private Cooperation.* The Forum engages the foremost political, business, cultural and other leaders of society to shape global, regional and industry agendas.

It was established in 1971 as a not-for-profit foundation and is headquartered in Geneva, Switzerland. It is independent, impartial and not tied to any special interests. The Forum strives in all its efforts to demonstrate entrepreneurship in the global public interest while upholding the highest standards of governance. Moral and intellectual integrity is at the heart of everything it does.

Our activities are shaped by a unique institutional culture founded on the stakeholder theory, which asserts that an organization is accountable to all parts of society. The institution carefully blends and balances the best of many kinds of organizations, from both the public and private sectors, international organizations and academic institutions.


We believe that progress happens by bringing together people from all walks of life who have the drive and the influence to make positive change.

Read the latest Annual Report [here](#). Find out about our Foundation [Regulations](#) and [Statutes](#).”

<https://www.weforum.org/about/world-economic-forum>

“World Economic Forum Partners are leading global companies developing solutions to the world’s greatest challenges. They are the driving force behind the Forum’s programmes. Our Partners engage in Forum Platforms to shape the future, accessing networks and experts to ensure strategic decision-making on the most pressing world issues.”

<https://www.weforum.org/partners>



<https://intelligence.weforum.org/topics/a1G0X000006O6EHUA0?tab=publications>



# GAVI, officially Gavi, the Vaccine Alliance

(previously the **GAVI Alliance**, and before that the **Global Alliance for Vaccines and Immunization**)

“GAVI facilitates vaccinations in developing countries by working with donor governments, the [World Health Organization](#),<sup>[4]</sup> [UNICEF](#),<sup>[5]</sup> the [World Bank](#),<sup>[6]</sup> the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society, the [Bill & Melinda Gates Foundation](#)<sup>[7]</sup> and other private philanthropists. GAVI has observer status at the [World Health Assembly](#).”

<https://en.wikipedia.org/wiki/GAVI>


„Die Impfallianz Gavi wurde am 29. Januar 2000 am **Weltwirtschaftsforum (WEF – World Economic Forum)** in **Davos** ins Leben gerufen. “

<https://www.savethechildren.de/news/20-jahre-im-einsatz-fuer-kinder-die-impfallianz-gavi/>



<https://www.gavi.org/our-alliance/about>

# GAVI - Direct connections (extract of entire link analysis)



# GAVI has full immunity in Switzerland

## Abkommen

zwischen dem **Schweizerischen Bundesrat** und **GAVI Alliance** (Global Alliance for Vaccines and Immunization) zur Regelung des rechtlichen Statuts von GAVI Alliance in der Schweiz

<https://www.fedlex.admin.ch/eli/cc/2009/541/de>

(Stand am 1. Januar 2009)

<sup>1</sup> Der Originaltext findet sich unter der gleichen Nummer in der französischen Ausgabe dieser Sammlung.

Der Schweizerische Bundesrat

einerseits

und

GAVI Alliance (Global Alliance for Vaccines and Immunization)

andererseits,

in dem Wunsche, ihre Beziehungen in einem Sitzabkommen zu regeln,

sind wie folgt übereingekommen:

### - **I. Statut, Vorrechte und Immunitäten von GAVI Alliance**

#### - **Art. 1 Persönlichkeit und Rechtsfähigkeit**

Der Schweizerische Bundesrat anerkennt die internationale Rechtspersönlichkeit und die Rechtsfähigkeit von GAVI Alliance in der Schweiz.

#### - **Art. 2 Unabhängigkeit und Handlungsfreiheit**

1. Der Schweizerische Bundesrat garantiert GAVI Alliance Unabhängigkeit und Handlungsfreiheit.

2. Er gewährt ihr die uneingeschränkte Versammlungsfreiheit, einschliesslich der Rede-, Beschluss- und Publikationsfreiheit, auf dem Hoheitsgebiet der Schweiz.

#### - **Art. 3 Unverletzbarkeit der Räumlichkeiten**

Die Gebäude oder Gebäudeteile und das anliegende Gelände, die von GAVI Alliance für ihre eigenen Zwecke benützt werden, sind ungeachtet der herrschenden Eigentumsverhältnisse unverletzbar. Kein Vertreter schweizerischer Behörden darf sie ohne ausdrückliche Zustimmung des Exekutivdirektors von GAVI Alliance oder der von ihm bezeichneten Person betreten.

#### - **Art. 4 Unverletzbarkeit der Archive**

Die Archive von GAVI Alliance und alle ihr gehörenden oder in ihrem Besitz befindlichen Dokumente und Datenträger ganz allgemein sind jederzeit und überall unverletzbar.

#### - **Art. 5 Immunität von der Gerichtsbarkeit und der Vollstreckung**

1. Im Rahmen ihrer Tätigkeit geniesst GAVI Alliance Immunität von der Gerichtsbarkeit und der Vollstreckung, ausser:

- a) wenn diese Befreiung im Einzelfall vom Exekutivdirektor oder durch die von ihm bezeichnete Person ausdrücklich aufgehoben worden ist;
- b) im Falle einer gegen GAVI Alliance angestregten zivilrechtlichen Haftungsklage wegen eines Schadens, der durch ein GAVI Alliance gehörendes oder auf ihre Rechnung betriebenes Kraftfahrzeug verursacht wurde;
- c) im Falle einer durch richterlichen Entscheid angeordneten Beschlagnahme von Gehältern, Löhnen und anderen Bezügen, welche GAVI Alliance einem ihrer Beamten schuldet;
- d) im Falle einer Widerklage, die in unmittelbarem Zusammenhang mit einer von GAVI Alliance erhobenen Hauptklage steht; und
- e) im Falle der Vollstreckung einer schiedsrichterlichen Entscheidung, welche in Anwendung von Artikel 29 dieses Abkommens gefällt wurde.

2. Die Gebäude oder Gebäudeteile, das anliegende Gelände sowie die Vermögenswerte, die sich im Eigentum von GAVI Alliance befinden oder von ihr zu ihren Zwecken benutzt werden, sind unabhängig von ihrem Standort und ihrem Besitzer befreit von:

- a) jeglicher Form von Requisition, Beschlagnahme oder Enteignung;
- b) jeglicher Form von Zwangsvollstreckung, anderen behördlichen Zwangsmassnahmen oder Massnahmen, die einem Urteil vorausgehen, mit Ausnahme der in Absatz 1 vorgesehenen Fälle.

#### - **Art. 6 Veröffentlichungen und Mitteilungen**

## CEPI - Coalition for Epidemic Preparedness Innovations


**CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome, and the World Economic Forum.**

To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Ethiopia, Finland, Germany, Hungary, Iceland, Indonesia, Italy, Japan, Kuwait, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Romania, Saudi Arabia, Serbia, Singapore, Switzerland, The Republic of Korea, United Kingdom, USAID, and Wellcome.

<https://cepi.net/about/whoweare/>



# CEPI - Coalition for Epidemic Preparedness Innovations






# CEPI - Coalition for Epidemic Preparedness Innovations

This link analysis shows direct path of people are shown in previous graph.

Please have a look at separate file:

Corina\_Network\_CEPI\_PeopleAndTheirDirectPath\_2021-09-12.png



## FIND

**“FIND, the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnosis around the world.**

We connect countries and communities, funders, decisionmakers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems.

We are working to save 1 million lives through accessible, quality diagnosis, and save US\$1 billion in healthcare costs to patients and health systems. We are co-convenor of the [Access to COVID-19 Tools \(ACT\) Accelerator](#) diagnostics pillar, and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic”


<https://www.finddx.org/about/>

<https://www.finddx.org/>

<https://dndi.org/press-releases/2010/international-status-granted/>

[https://en.wikipedia.org/wiki/Foundation\\_for\\_Innovative\\_New\\_Diagnostics](https://en.wikipedia.org/wiki/Foundation_for_Innovative_New_Diagnostics)

# FIND



# COVAX / ACT-A

# COVAX

With a fast-moving pandemic, no one is safe, unless everyone is safe

COVAX is co-led by CEPI, Gavi and WHO, alongside key delivery partner UNICEF. In the Americas, the PAHO Revolving Fund is the recognized procurement agent for COVAX.



<https://www.who.int/initiatives/act-accelerator/covax>

<https://www.gavi.org/vaccineswork/covax-explained>

<https://en.wikipedia.org/wiki/COVAX>

## 2,2 Milliarden Euro für Impfungen, Diagnostik und Medikamente


Die Pandemie kann nur besiegt werden, wenn sie weltweit unter Kontrolle gebracht wird: Deutschland hat sich deshalb schon früh für eine gemeinsame und solidarische Antwort auf die Pandemie stark gemacht. Nach dem Grundsatz „Niemand ist sicher, bis alle sicher sind“ hat Deutschland im vergangenen Jahr den Koordinierungsmechanismus Access to Covid-19 Tools Accelerator (ACT-A) mitgegründet. Als derzeit zweitgrößter Geber von ACT-A hat Deutschland bislang 2,2 Milliarden Euro zur Verfügung gestellt. Der Großteil der Unterstützung geht an die internationale Impfstoffplattform COVAX, ein Teil wird auch für Diagnostik und Medikamente gegen die Krankheit verwendet. Bis Anfang August wurden dadurch bereits 138 Staaten mit insgesamt über 200 Millionen Dosen der Impfstoffe von AstraZeneca, Johnson & Johnson, Moderna und BioNTech versorgt.

Auszug aus <https://www.auswaertiges-amt.de/de/aussenpolitik/themen/gesundheits/covax/2395748> vom 26.08.2021

Weiterführende Links:

<https://www.who.int/initiatives/act-accelerator>

<https://www.gavi.org/covax-facility>



# The Global Fund

„Der **Globale Fonds zur Bekämpfung von AIDS, Tuberkulose und Malaria** ([englisch](#) **The Global Fund to Fight AIDS, Tuberculosis and Malaria**, kurz GFATM) mit Sitz in [Genf](#), [Schweiz](#), ist ein Finanzierungsinstrument zur Bekämpfung der drei großen Infektionskrankheiten [AIDS](#), [Tuberkulose](#) und [Malaria](#). Der weltweit in mehr als 100 Ländern tätige Fonds ist eines der wichtigsten Instrumente zur Bekämpfung dieser Krankheiten.“

„Der Fonds wurde im Jahr 2002 gegründet, nachdem sich die [G8](#)-Staaten auf ihrem [Treffen in Genua 2001](#) darauf verständigt hatten, die Finanzierung des weltweiten Kampfes gegen die drei schweren Infektionskrankheiten AIDS, Tuberkulose und Malaria zu verstärken. Schon ein Jahr zuvor forderte der ehemalige [UN-Generalsekretär Kofi Annan](#) die Einrichtung eines solchen Fonds<sup>[2]</sup>. Der Fonds dient der Finanzierung nationaler Maßnahmen gegen die drei Krankheiten einschließlich der Stärkung von Gesundheitssystemen. Er fördert zudem die Eigenverantwortung der Regierungen, die Mitwirkung der Zivilgesellschaft und des privaten Sektors sowie wirkungs- und genderorientierte Maßnahmen gegen Aids, Tuberkulose und Malaria. Der ehemalige Leiter des US-AIDS-Programms PEPFAR (President's Emergency Plan for AIDS Relief), Mark Dybul, wurde im Jahre 2012 zum Leiter des Globalen Fonds gewählt. Er hatte dieses Amt bis Mai 2017 inne. Mark Dybul gilt in Fachkreisen als Visionär im Bereich globaler Gesundheit und hatte maßgeblich an der Gründung und Durchführung des Notfallplans des US-Präsidenten für AIDS-Bekämpfung (PEPFAR) beigetragen. Als Arzt mit dem Schwerpunkt Immunologie wurde er als Mediziner, Wissenschaftler und strategisch denkender Verwalter zum ausgewiesenen HIV- und AIDS-Experten. Nach dem Abschied von Mark Dybul leitete Marijke Wijnroks vorübergehend die Organisation. Seit März 2018 ist [Peter Sands](#) Direktor des GFATM.“

„Deutschland und der Globale Fonds

Als viertgrößter Geber (nach den USA, Frankreich und Großbritannien) leistet Deutschland einen bedeutenden Beitrag zur weltweiten Bekämpfung von AIDS, Tuberkulose und Malaria.<sup>[13]</sup> Zudem spielt das Land als Mitglied des Verwaltungsrats eine entscheidende Rolle dabei, den globalen Fonds bei der Umstrukturierung und Straffung von dessen Betriebsabläufen zu unterstützen, damit die Investitionen der Organisation durchdacht getätigt werden und auf maximale Wirkung ausgerichtet sind. Außerdem hat der Fonds ein neues Finanzierungsmodell eingeführt. Durch das neue Finanzierungsmodell wird eine stärkere Verantwortung der Länder für Projekte gefördert. Zudem wirkt das neue Finanzierungsmodell als Anreiz für politischen Dialog mit den Programmdurchführungsländern und zielt gleichzeitig auf die Berücksichtigung von Themen der Gleichberechtigung von Männern und Frauen sowie der sexuellen und reproduktiven Gesundheit und von Menschenrechtsbelangen ab. Der Landesdialog als Schlüsselement des neuen Finanzierungsmodells bietet außerdem neue Chancen für das Engagement aller Partner, auch aus der Zivilgesellschaft und der freien Wirtschaft. Neben diesen Beiträgen ist Deutschland auch einer der führenden Schirmherren des Programms Debt2Health des Globalen Fonds, das weltweit zu einem erheblichen Anstieg der Förderung von Programmen des Globalen Fonds geführt hat. Im Rahmen dieser Initiative hat Deutschland in Ländern wie Côte d'Ivoire, Indonesien, Pakistan und Ägypten einen Schuldenschnitt vorgenommen.“

[https://de.wikipedia.org/wiki/Global\\_Fund](https://de.wikipedia.org/wiki/Global_Fund)

[https://en.wikipedia.org/wiki/The\\_Global\\_Fund\\_to\\_Fight\\_AIDS,\\_Tuberculosis\\_and\\_Malaria](https://en.wikipedia.org/wiki/The_Global_Fund_to_Fight_AIDS,_Tuberculosis_and_Malaria)

<https://www.theglobalfund.org/en/overview/>

<https://www.theglobalfund.org/en/>

<https://www.theglobalfund.org/en/board/>


<https://www.theglobalfund.org/en/private-ngo-partners/resource-mobilization/bill-melinda-gates-foundation/>



Melinda Gates



Bill Gates



Direct grants from Bill & Melinda Gates Foundation (BMGF) to

- Swiss Agency for Therapeutic Products, Switzerland
- Charite, Germany
- RKI - Robert Koch Institut, Germany
- MHRA – Medicines & Healthcare products regulatory Agency, United Kingdom
  
- European Commission

Committed Grants; sort by Date Descending

Date Descending



GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Swiss Agency for Therapeutic Products	Global Health	FEBRUARY 2020	GLOBAL (+1)	\$900,000
	GRANT TOPIC Development of Solutions to Improve Global Health	DURATION (MONTHS) 46	GRANTEE LOCATION Berne, Switzerland	
Swiss Agency for Therapeutic Products	Global Health	DECEMBER 2015	GLOBAL (+1)	\$1,332,000
	GRANT TOPIC Development of Solutions to Improve Global Health	DURATION (MONTHS) 67	GRANTEE LOCATION Berne, Switzerland	
Swiss Agency for Development and Cooperation	Global Growth & Opportunity	SEPTEMBER 2010	GLOBAL (+2)	\$453,381
	GRANT TOPIC Water, Sanitation and Hygiene	DURATION (MONTHS) 48	GRANTEE LOCATION Bern, Switzerland	

<https://www.gatesfoundation.org/about/committed-grants?q=Swiss%20Agency>

<https://www.swissmedic.ch/swissmedic/de/home/ueber-uns/internationale-zusammenarbeit/multilaterale-zusammenarbeit-mit-internationalen-organisationen-/bill-and-melinda-gates-foundation.html>

Show 10



Date Last Updated: 8.23.2021

Committed Grants; sort by Date Descending

Date Descending ▾

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Charité - Universitätsmedizin Berlin	Global Health	MARCH 2020	GLOBAL	\$249,550
	GRANT TOPIC Support Innovative Technology Solutions	DURATION (MONTHS) 40	GRANTEE LOCATION Berlin, Germany	

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Charité - Universitätsmedizin Berlin	Global Health	DECEMBER 2019	GLOBAL	\$86,181
	GRANT TOPIC Pneumonia	DURATION (MONTHS) 4	GRANTEE LOCATION Berlin, Germany	

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Charité - Universitätsmedizin Berlin	Global Policy and Advocacy	OCTOBER 2018	GLOBAL	\$549,999
	GRANT TOPIC Global Health and Development Public Awareness and Analysis	DURATION (MONTHS) 14	GRANTEE LOCATION Berlin, Germany	

<https://www.gatesfoundation.org/about/committed-grants?q=Charit%C3%A9>

Date Last Updated: 8.23.2021

Committed Grants; sort by Date Descending

Date Descending ▾

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Robert Koch Institute	Global Health	NOVEMBER 2019	GLOBAL	\$253,000
	GRANT TOPIC Vaccine Development	DURATION (MONTHS) 59	GRANTEE LOCATION Berlin, Berlin, Germany	

Show 10 ▾

<https://www.gatesfoundation.org/about/committed-grants?q=robert%20koch>

# MHRA awarded over **£980,000** for collaboration with the Bill and Melinda Gates Foundation and the World Health Organisation

MHRA today announced a partnership worth over £980,000 to improve the safety monitoring of medicines in low and middle-income countries.

From: [Medicines and Healthcare products Regulatory Agency](#)

Published 15 December 2017



**Medicines &  
Healthcare products  
Regulatory Agency**

We are delighted to announce a new partnership with the Bill & Melinda Gates Foundation and the World Health Organisation that aims to extensively improve the safety monitoring of medicines in low and middle-income countries (LMIC).

New medicines and vaccines, for diseases such as malaria and HIV, may be introduced for the first time in LMIC's where there are weak or no regulatory

<https://www.gov.uk/government/news/mhra-awarded-over-980000-for-collaboration-with-the-bill-and-melinda-gates-foundation-and-the-world-health-organisation>

## Related content

[Report of the Commission on Human Medicines Expert Working Group on Optimising Data on Medicines used During Pregnancy](#)

[Report of the Commission on Human Medicines' Expert Working Group on Hormone Pregnancy Tests](#)

[Safer Medicines in Pregnancy and Breastfeeding Consortium](#)

[Epilepsy medicines and pregnancy](#)

## Brexit

[Check what you need to do](#)

# **MHRA** and the Bill & Melinda Gates Foundation to look at the safer, effective use of medicines during pregnancy

MHRA and the Bill & Melinda Gates Foundation have begun new research on medicine use which could impact the health of pregnant women around the world.

From: [Medicines and Healthcare products Regulatory Agency](#)

Published **17 September 2019**



In advance of World Patient Safety Day (17 September), MHRA specialists, as part of a broader programme of work, have begun developing ground-breaking research to support the safer use of medicine during pregnancy.

**A \$360,000 grant over two years from the Bill & Melinda Gates Foundation** (approximately £292,000), will support the MHRA's research, to help predict the need for adjusting a medicine's dose during different trimesters of pregnancy. This will ensure effective use, which is vitally important for the health of mother and baby.

Worldwide, data in this area remain limited, and new insights could potentially impact the health of pregnant women around the world. This would also give obstetricians further clarity on the optimal dose of a

<https://www.gov.uk/government/news/mhra-and-the-bill-melinda-gates-foundation-to-look-at-the-safer-effective-use-of-medicines-during-pregnancy>

## Brexit

[Check what you need to do](#)

## Committed Grants; sort by Date Descending

Date Descending

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
European Commission	Global Development	MARCH 2020	GLOBAL <sup>+1</sup>	\$500,000
	GRANT TOPIC Nutrition	DURATION (MONTHS) 17	GRANTEE LOCATION Brussels, Belgium	
European Commission	Global Health	MARCH 2019	GLOBAL <sup>+1</sup>	\$45,178,000
	GRANT TOPIC Development of Solutions to Improve Global Health	DURATION (MONTHS) 238	GRANTEE LOCATION Brussels, Belgium	
European Centre for Development Policy Management	Global Policy and Advocacy	MARCH 2017	GLOBAL	\$399,982
	GRANT TOPIC Global Health and Development Public Awareness and Analysis	DURATION (MONTHS) 25	GRANTEE LOCATION Maastricht, Netherlands	
European Commission	Global Development	FEBRUARY 2016	GLOBAL <sup>+2</sup>	\$500,000
	GRANT TOPIC Nutrition	DURATION (MONTHS) 22	GRANTEE LOCATION Brussels, Belgium	
Imperial College London	Global Growth & Opportunity	SEPTEMBER 2010	GLOBAL <sup>+1</sup>	\$2,692,835
	GRANT TOPIC Agricultural Development	DURATION (MONTHS) 40	GRANTEE LOCATION London, United Kingdom	

<https://www.gatesfoundation.org/about/committed-grants?q=european%20commission>

## World Bank - Partners



<https://www.worldbank.org/en/topic/financialinclusion/overview#4>

[https://www.globalfinancingfacility.org/sites/gff\\_new/files/documents/GF-F-IG1-2\\_Participant%20List\\_%209\\_25.pdf](https://www.globalfinancingfacility.org/sites/gff_new/files/documents/GF-F-IG1-2_Participant%20List_%209_25.pdf)

CONTEXT

STRATEGY

RESULTS


**PARTNERS**

The World Bank Group works globally with standard-setting bodies to develop guidelines, standards and good practices. We also work with the G20 to develop guidance for regulators and policymakers and to catalyze new actions in support of financial inclusion. We are also an implementing partner for the G20 Global Partnership for Financial Inclusion (GPFII).


We also work closely with a number organizations and donor partners to advance financial inclusion, including Alliance for Financial Inclusion (AFI), AusAid, the Bill and Melinda Gates Foundation, DFID, Financial Sector Development Trusts, GIZ, the Ministry of Foreign Affairs of the Netherlands, the OECD, SECO, UNCDF, UNCITRAL, UNSGSA, USAID, and regional development banks.

The Ministry of Foreign Affairs of the Netherlands and the Bill and Melinda Gates Foundation provide the funding for the Financial Inclusion Support Framework (FISF), while SECO provides funding for the Consumer Protection and Financial Literacy (CPFL) program, and DFID provides funding for the Harnessing Innovation for Financial Inclusion (HiFi) program.


# World Bank




# IFC International Finance Corporation (World Bank)



# GFF – Global Financing Facility (World Bank)







# Some “Public Websites”

Please look at the people and organizations.

You’ll find some of them later in several link analysis.

## Mai 2017 / August 2018 Four new members complete the International Advisory Board on Global Health

<https://www.bundesgesundheitsministerium.de/english-version/press/2018/international-advisory-board.html>



Meeting in July with some members of the IAB and two Secretary of States (from left to right: Farrar, Roses, Hacker, Kickbusch, Secretary of State Stroppe, Nishtar, Elias, Schneider, Secretary of State Flachsbarth, Benn)

The Advisory Board consists of ten German and international experts. Six members of the International Advisory Board on Global Health have already been appointed by the Federal Ministry of Health in August 2017. Another four were appointed as members in May 2018. The Board now includes experts from different regions and stakeholder groups that have extensive expertise on various global health topics.

### Members of the International Advisory Board on Global Health

- Prof Dr Ilona Kickbusch, Director of the Global Health Centre at the Graduate Institute of International and Development Studies, Geneva (Chair of the board)
- Prof Dr Christian Drostén, Chair of the Institute of Virology at the Charité Berlin
- Dr Christopher Elias, President of the Global Development Program, Bill & Melinda Gates Foundation
- Dr Jeremy Farrar, Director of the Wellcome Trust
- Prof Dr Jörg Hacker, President of the German National Academy of Sciences Leopoldina
- Dr Matshidiso Rebecca Moeti, WHO Regional Director for Afrika
- Dr Mirta Roses Periago, former Director of the Pan American Health Organization
- Dr Sania Nishtar, President of Heartfile
- Dr Gisela Schneider, Director of the German Institute for Medical Mission
- Dr Christoph Benn, Director for External Relations of the Global Fund to Fight AIDS.

Mai 2018

# WHO Global Preparedness Monitoring Board

The Global Preparedness Monitoring Board is a joint arm of the WHO and the World Bank.

Created in response to recommendations by the UN Secretary General's [Global Health Crises Task Force in 2017](#), the GPMB was co-convened by the World Health Organization and the World Bank Group and formally launched in May 2018

<https://apps.who.int/gpmb/>

Co-chairs

[Board Members](#)

Co-conveners



**Dr Victor Dzau**

*President of the US National Academy of Medicine, USA*




**Dr Chris Elias**

*President, Global Development Program, Bill & Melinda Gates Foundation, USA*



**Sir Jeremy Farrar**

*Director, Wellcome Trust, UK*



**Dr Anthony S Fauci**

*Director, National Institute of Allergy and Infectious Diseases, USA*



**Ms Henrietta Fore**

*Executive Director, UNICEF*



**Dr George F. Gao**

*Director-General, Chinese Center for Disease Control and Prevention, People's Republic of China*



**H.E. Sigrid Kaag**

*Minister for Foreign Trade and Development Cooperation, The Netherlands*



**Prof Ilona Kickbusch**

*Chair of the International Advisory Board of the Global Health Centre at the Graduate Institute of International*



**Dr Ngamiye M. Daniel**

*Minister of Health, Republic of Rwanda*

Alle Referenten



**Hermann Gröhe**

Stellvertretender Vorsitzender der CDU/CSU-Bundestagsfraktion |  
Beauftragter für Kirchen und Religionsgemeinschaften



**Ralph Brinkhaus**

Vorsitzender der CDU/CSU-Fraktion im Deutschen Bundestag



**Dr. Angela Merkel**

Bundeskanzlerin der Bundesrepublik Deutschland



**Prof. Ilona Kickbusch PHD**

Graduate Institute of International and Development Studies  
Geneva

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



**Dr. Tedros Adhanom Ghebreyesus**

Generaldirektor der Weltgesundheitsorganisation

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



**Prof. Dr. Christian Drosten**

Institut für Virologie Charité – Universitätsmedizin Berlin

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



**Prof. Dr. Clarissa Prazeres da Costa**

Institut für Medizinische Mikrobiologie, Immunologie und Hygiene |  
Technische Universität München

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



**Joe Cerrell**

Geschäftsführender Direktor Globale Politik | Bill and Melinda Gates  
Foundation

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



**Prof. Jeremy Farrar**

Direktor Wellcome Trust

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



**Dr. Georg Kippels**



**Jens Spahn**

Bundesminister für Gesundheit

**8. Mai 2019**

CDU Veranstaltung – Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen

<https://www.cducsu.de/veranstaltungen/globale-gesundheit-st-rken-un-nachhaltigkeitsziel-umsetzen/referenten>

# Global Health Hub Germany

The Global Health Hub Germany is a network that aims to bring together all actors interested in Global Health. The Hub wants to promote exchange, initiate new partnerships, support cooperation and innovative approaches - across sectors and stakeholder groups.

Membership is open to both individuals and organizations from all areas and sectors involved in Global Health - stakeholders from science, the private sector, civil society and politics, as well as from the health, environment, climate, food, agriculture, education and research sectors.


**The Hub was inaugurated by Minister of Health Jens Spahn in February 2019 with a kick-off event at the Federal Ministry of Health. The Ministry of Health is providing funding for three years (2019-2021) for the set-up of the Hub and the establishment of the office.**

Since the kick-off, the number of members has increased continuously: more than 1150 individuals and organizations have by now registered to make new contacts, exchange views on current issues and work together.

To promote cooperation and exchange, the Hub offers various possibilities and formats:

- Members can collaborate in cross-sectoral and cross-actor working groups on issues of their choice. Approximately 20 working groups have already been established on topics such as "Universal health coverage through digital technology", "Climate and Health" or "Global Mental Health". In the "Virtual Working Space", in the members only area of the website, interested members can join the already existing working groups to collaborate and discuss. Your topic is not included yet? No problem, you can suggest a new working group and search for fellow members who are interested in working on the same topic.
- With different types of events the Hub promotes regular exchange between members. In addition to face-to-face events, such as the annual Global Health Talk, webinars are held regularly to discuss current topics or present the work of the members.
- All registered members can be found in the member database in the members only area of the website. There you can search for experts on specific topics or from specific stakeholder groups. You can send networking requests, exchange views and discuss via the website by using the chat feature.
- In an interactive forum all members can informally exchange information, ask questions or give advice.


<https://www.globalhealthhub.de/index.php/en/content/about-hub>



The screenshot shows the website's navigation bar with the logo and menu items: ABOUT, EVENTS CALENDAR, NEWS, WORKING GROUPS, LOGIN, REGISTER, EN, DE. The main heading is "Steering Committee". Below it, a paragraph states: "The Steering Committee is responsible for the strategic planning, further development and direction of the Hub. The Steering Committee consists of 16 representatives who on a parity basis represent the stakeholder groups science, private sector, civil society and youth as well as think tanks, foundations, the parliament and international organizations." A section titled "Foundations" lists: Caroline Schmutte, Wellcome Trust; and Tobias Kahler, Bill & Melinda Gates Foundation.

<https://www.globalhealthhub.de/en/content/steering-committee>

# Global Health Hub Germany



## Advisory Board on Global Health (Germany)

Jens Spahn

29. Juli 2019

<https://www.globalhealthhub.de/en/news/international-advisory-board-germanys-opportunities-shaping-global-health>



29 JUL. 2019 | GLOBAL | BY: JULIA SCHMIDT

# Event 201

18. Oktober 2019

<https://www.centerforhealthsecurity.org/event201/>

Players:

<https://www.centerforhealthsecurity.org/event201/players/index.html>

Video posted by John Hopkins University:

<https://www.youtube.com/watch?v=AoLw-Q8X174&list=PL9-oVXQX88esnrdhaiuRdXGG7XOVYB9Xm>



Event 201 was supported by funding from the Open Philanthropy Project.

<https://www.centerforhealthsecurity.org/event201/about>



Latoya Abbott



Sofia Borges



Brad Connett



Christopher Elias



Tim Evans



George Gao



Avril Haines



Jane Halton



Matthew Harrington



Martin Knuchel



Eduardo Martinez



Stephen Redd



Hasti Taghi



Adrian Thomas



Lavan Thiru



# World Health Summit

## Berlin, Germany

### #WHS2021 SPEAKERS



[See more](#)

<https://www.worldhealthsummit.org/summit/speakers.html>

[Home](#) > [Partners](#) > [Sponsoring Partners](#)

## SPONSORING AND SUPPORTING PARTNERS



### NEWSLETTER

Get insights on global health, read about M8 Alliance and community activities, and stay up-to-date with the World Health Summit program: Sign up for our newsletter here

### PATRONS 2021

The World Health Summit is traditionally held under the patronage of:

**Angela Merkel**  
Chancellor of the Federal Republic of Germany

**Emmanuel Macron**  
President of the French Republic

**Ursula von der Leyen**  
President of the European Commission

**Tedros Adhanom Ghebreyesus**  
Director-General of the World Health Organization (WHO)

### KAMPALA DECLARATION

The World Health Summit Regional Meeting in Uganda ended with the Kampala Declaration on COVID-19 Vaccine Equity, signed by the Director-General of WHO, the President of Uganda, several ministers from Africa, the M8 Alliance, and the World Health Summit.

Find the declaration and all details on the Regional Meeting here



### M8 ALLIANCE EXPERT MEETINGS 2021

Next Webinar: November 30, 2021

[More information](#)

### WORLD HEALTH SUMMIT PRESIDENT

Axel R. Pries, Dean of Charité - Universitätsmedizin Berlin is World Health Summit President since 2021.  
[Read more](#)

<https://www.worldhealthsummit.org/partner/sponsoring-partners.html>

### STRATEGIC PARTNERS



### MAJOR PARTNERS




### GENERAL PARTNERS



### SUPPORTING PARTNERS



# Jens Spahn, CDU, Bundesgesundheitsminister



<https://www.tagesspiegel.de/politik/privater-immobiliendeal-des-gesundheitsministers-jens-spahn-ist-seiner-verantwortung-nicht-gerecht-geworden/26741038.html>

<https://www.spiegel.de/politik/deutschland/jens-spahn-villa-in-berlin-dahlem-kostete-4-125-millionen-euro-a-d8a665b4-4746-4ce8-898b-a1eb6713b0dd>

[https://lobbypedia.de/wiki/Jens\\_Spahn](https://lobbypedia.de/wiki/Jens_Spahn)

[https://de.wikipedia.org/wiki/Jens\\_Spahn](https://de.wikipedia.org/wiki/Jens_Spahn) <https://cdn.businessinsider.de/wp-content/uploads/2021/04/Liste.pdf> (Jens Spahn - please see page 4 and 5)

**welt** Ticker Suchen Anmelden ABONNEMENT

HOME LIVE-TV MEDIATHEK WELTPLUS BUNDESLIGA POLITIK WIRTSCHAFT SPORT PANORAMA WIS MEHR PRODUKTE

**NEWTICKER** **DIE NACHRICHTEN HEUTE** Newsicker, Schlagzeilen und alles, was heute wichtig ist im Überblick. ZUM NEWTICKER

HOME PANORAMA Peter Piot: „Ohne einen Coronavirus-Impfstoff werden wir nie wieder normal leben können“

## PANORAMA


CORONAVIRUS-LIVETICKER CORONAVIRUS: ALLE KARTEN UND ZAHLEN

**WELT:** PETER PIOT

### „Ohne einen Coronavirus-Impfstoff werden wir nie wieder normal leben können“

Veröffentlicht am **13.05.2020** | Lesedauer: 4 Minuten


Von **Cornelia Karin Hendrich**  
Redakteurin



Peter Piot warnt: Das Coronavirus sei eine "lebensverändernde Erfahrung".  
Quelle: FABRICE COFFRANT/ITV via Getty Images

Einen Hauch des Todes habe er bei seiner Begegnung mit Covid-19 gespürt, sagt Peter Piot. Der Arzt und Wissenschaftler berät Ursula von der Leyen, zuletzt war er selbst an Corona erkrankt. Ohne Impfstoff werde es kein normales Leben mehr geben.

Der Wissenschaftler und Arzt Peter Piot, Mitentdecker des Ebola-Virus, hat nach seiner eigenen Erkrankung mit Covid-19 vor Langzeitfolgen des neuartigen Coronavirus für viele Menschen gewarnt. Der vielfach ausgezeichnete Forscher, der auch Sonderberater der Präsidentin der EU-Kommission, Ursula von der Leyen, ist, sagte: „Es wird weltweit Hunderttausende von Menschen geben, möglicherweise mehr, die für den Rest ihres Lebens Behandlungen wie eine Dialyse benötigen.“

 **European Commission** Search

Home Research and Innovation Events Upcoming events European Research and Innovation Days Speakers Peter Piot

## Peter Piot

Peter Piot is the Director of the London School of Hygiene & Tropical Medicine and Special Advisor to the President of the European Commission on COVID-19. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations from 1995 until 2008. He co-discovered the Ebola virus in 1976 and conducted pioneering research on HIV/AIDS.

**Organization**  
London School of Hygiene & Tropical Medicine

**Position**  
Director

See all speakers

**Share this page**

Twitter Facebook LinkedIn E-mail More share options

**European Commission website**

This site is managed by the Directorate-General for Research and Innovation

More information on:  
Strategy  
About the European Commission  
Business, Economy, Euro

Aid, Development cooperation, Fundamental rights  
Food, Farming, Fisheries  
EU regional and urban development

<https://ec.europa.eu/research-and-innovation/en/events/upcoming-events/research-innovation-days/speakers/peter-piot>  
[https://www.leopoldina.org/fileadmin/redaktion/Mitglieder/CV\\_Piot\\_Peter\\_EN.pdf](https://www.leopoldina.org/fileadmin/redaktion/Mitglieder/CV_Piot_Peter_EN.pdf)

Menu **BILL & MELINDA GATES Foundation** Search

Home Ideas Media Center Dr. Peter Piot Joins Foundation as a Senior Fellow

## Dr. Peter Piot Joins Foundation as a Senior Fellow - Bill & Melinda Gates Foundation

**Media contact**

**Phone:**  
206-709-3400 ↗

**Mail:**  
[media@gatesfoundation.org](mailto:media@gatesfoundation.org) →

📧 📞 📍 🌐

**Share** ↕

Bill & Melinda Gates Foundation  
Phone: +1.206.709.3400  
Email: [media@gatesfoundation.org](mailto:media@gatesfoundation.org)

SEATTLE -- The Bill & Melinda Gates Foundation announced today that Peter Piot, M.D., Ph.D., has joined the foundation's Global Health Program as a senior fellow until April 30. A distinguished academic and accomplished leader in the global effort to fight HIV/AIDS, Piot served from 1995 to 2008 as the founding executive director of the Joint United Nations Program on HIV/AIDS (UNAIDS).

"Peter is a rigorous scientist and a passionate advocate for global health," said Dr. Tachi Yamada, president of the foundation's Global Health Program. "The foundation and our partners will benefit greatly from his deep experience and his insight into the health challenges facing developing countries."

As a senior fellow, Piot will advise the foundation on its global health strategy, including its support for efforts to fight HIV/AIDS and other infectious diseases.


"I am encouraged by the growing enthusiasm and support for improving health in the developing world," said Dr. Piot. "The Gates Foundation has played a central role in making this progress possible, and I look forward to working closely with my colleagues at the foundation to build on this momentum."

While at UNAIDS, Piot built a broad international coalition against the global HIV/AIDS epidemic, including both governments and civil society groups. He successfully advocated for increased funding for and attention to the epidemic. Global investments to fight HIV/AIDS grew from \$250 million in 1996 to \$10 billion in 2007.


Piot holds a medical degree from the University of Ghent in Belgium. In 1976, while in Zaire pursuing his Ph.D. in microbiology, he co-discovered the Ebola virus. Piot has held several academic positions and pioneered a series of collaborative programs in sub-Saharan Africa, including Project SIDA in Kinshasa, Zaire, the first international program on HIV in Africa.

<https://www.gatesfoundation.org/ideas/media-center/press-releases/2009/01/dr-peter-piot-joins-foundation-as-a-senior-fellow>

# Connection between BMGF, European Commission, Peter Piot, Emer Cooke (EMA), Heidi Larson (VCP), EFPIA



# Connection between BMGF, European Commission, Peter Piot, Emer Cooke (EMA), Heidi Larson (VCP), EFPIA, Lothar Wieler, Christian Drosten



# Hans-Ulrich Holtherm - Neu im Bundesgesundheitsministerium – 03/2020

aerzteblatt.de

/ Ärzteblatt / cme / Ärztestellen / Studieren / English Edition

Home Archiv News Themen DÄ plus Politik Medizin

Archiv > Deutsches Ärzteblatt > 11/2020 > Hans-Ulrich Holtherm: Neu im Bundesgesundheitsministerium

PERSONALIEN

## Hans-Ulrich Holtherm: Neu im Bundesgesundheitsministerium

Dtsch Arztebl 2020; 117(11): A-557 / B-481

Bearheide, Rebecca



Artikel Briefe & Kommentare Statistik

Seit dem 1. März leitet Generalarzt Dr. med. Hans-Ulrich Holtherm (55) die im Bundesgesundheitsministerium (BMG) neu geschaffene Abteilung 6 „Gesundheitsschutz, Gesundheitssicherheit, Nachhaltigkeit“. In der Abteilung gibt es zwei Unterabteilungen mit jeweils fünf Fachreferaten, dazu zählen Referate zum nationalen und internationalen Krisenmanagement.

„Dr. Hans-Ulrich Holtherm verbindet durch seine langjährigen Erfahrungen die Themen Gesundheit und Sicherheit im gesamtgesellschaftlichen Ansatz und ist daher Sinnbild für die neue Abteilung 6“, heißt es zur Personalie aus dem Ministerium. Der Kommandeur und Ärztliche Direktor des Bundeswehrkrankenhauses Ulm, bei dem er seinen Dienst erst im Januar 2020 antrat, sei Experte in Fragen des öffentlichen Gesundheitsdienstes im Inland sowie durch Erfahrungen mit der Bundeswehr im Ausland auch „sachkundig in der Krisenreaktion und -prävention“, so das BMG. Die Gründung dieser neuen Abteilung wurde schon 2019 beschlossen.



Hans-Ulrich Holtherm, Foto: Bundeswehr

Anzeige

Holtherm war bei Auslandseinsätzen im Irak, Afghanistan, im Kongo, in Dschibuti und im Kosovo. Der Generalarzt war bereits 2009 im Zuge der H1N1-Pandemie von der Bundeswehr abgeordnet in das BMG und gehörte auch 2014 dem ressortübergreifenden Ebola-Krisenstab an. 1964 in Rheine geboren, trat er 1983 in die Bundeswehr ein und studierte als Sanitätsoffiziersanwärter in Münster Humanmedizin. Er ist Allgemeinmediziner, Facharzt für Öffentliches Gesundheitswesen mit Zusatzqualifikationen in Tropen-, Flug- und Betriebsmedizin. Rebecca Beerheide

<https://www.aerzteblatt.de/archiv/213019/Hans-Ulrich-Holtherm-Neu-im-Bun%C2%ADdes%C2%ADge%C2%ADsund%C2%ADheits%C2%ADmi%C2%ADnis%C2%ADter%C2%ADium>

[https://de.wikipedia.org/wiki/Hans-Ulrich\\_Holtherm](https://de.wikipedia.org/wiki/Hans-Ulrich_Holtherm)

# Paul Zubeil - Neu im Bundesgesundheitsministerium – 02/2021

Paul Zubeil

## Ehemann von Hendrik Streeck tritt Stelle im Gesundheitsministerium an

8. Februar 2021 um 16:07 Uhr | Lesedauer: 5 Minuten



Das Bundesgesundheitsministerium hat seinen Sitz in Bonn. Foto: Benjamin Westhoff

Bonn. Der Ehemann des Bonner Virologen Hendrik Streeck, Paul Zubeil, hat am Montag eine Stelle im Bundesgesundheitsministerium am Dienort Bonn angetreten. Er ist dort Unterabteilungsleiter für europäische und internationale Angelegenheiten.

[https://ga.de/bonn/stadt-bonn/partner-von-hendrik-streeck-paul-zubeil-arbeitet-fuer-das-bundesgesundheitsministerium\\_aid-56131801](https://ga.de/bonn/stadt-bonn/partner-von-hendrik-streeck-paul-zubeil-arbeitet-fuer-das-bundesgesundheitsministerium_aid-56131801)



## Unsere Kollaborationen in den Bereichen Infektionskrankheiten und seltene Erkrankungen

### Genevant

- Seit 2018 Co-Entwicklungs- und -Kommerzialisierungspartner für fünf mRNA-Proteinersatztherapien bei seltenen Erkrankungen; 50:50 globale Kosten- und Gewinnaufteilung

- Fünf exklusive Onkologie-LNP-Lizenzen für BioNTech. Genevant ist berechtigt, bedeutende kommerzielle Meilensteine für die Onkologie-Lizenzen zu erhalten

### Pfizer

- Seit 2018 bestehende Lizenzierungsvereinbarung zur gemeinsamen Entwicklung eines prophylaktischen Grippeimpfstoffs auf mRNA-Basis (BNT161)

- Vorabzahlung, Kapitalinvestition und erste Meilensteinzahlungen in Höhe von 120 Mio. \$

- Bis zu 325 Mio. \$ an möglichen weiteren Meilensteinzahlungen

- Lizenzgebühren auf weltweiten Absatz auf weltweiten Nettoumsatz im Falle einer Marktzulassung

### University of Pennsylvania (UPenn)

- Seit 2018 strategische Forschungs- und Entwicklungskooperation mit der exklusiven Option, mRNA-Immuntherapien zur Behandlung von bis zu zehn Indikationen von Infektionskrankheiten zu entwickeln und zu vermarkten

- Unterstützung der Forschungsaktivitäten seitens BioNTech mit 20 Mio. \$

- UPenn führt die präklinischen Studien durch

- BioNTech behält die Option, die mRNA-Impfstoffkandidaten für die klinische Entwicklung zu lizenzieren

### Bill & Melinda Gates Foundation

- Seit 2019 Forschungs- und Entwicklungsvereinbarung im Bereich HIV und Tuberkulose (TB) sowie bis zu drei weiteren Infektionskrankheiten

- 55 Mio. \$ als Equity-Investition in die Entwicklung weiterer Strategien zur Prävention und/oder Behandlung von HIV und TB

- Zuschüsse in Höhe von bis zu 45 Mio. \$ zur Finanzierung zusätzlicher Aktivitäten in bis zu drei weiteren Projekten im Bereich Infektionskrankheiten innerhalb der ersten fünf Jahre der Zusammenarbeit

Epitop, welches in Bauchspeicheldrüsenkrebs und anderen gastrointestinalen Krebsarten exprimiert wird und dort eine Rolle bei der Tumordhäsion und Metastasenbildung spielt.

Im Juni 2019 gab BioNTech den Start der klinischen Entwicklung von Produktkandidat DuoBody®-PD-L1x4-1BB bekannt. PD-L1x4-1BB ist ein bi-spezifischer Antikörper, der gemeinsam mit Gemab A/S entwickelt wird. Im Rahmen der Phase-1/2a-Studie wird der bi-spezifische Antikörper in Patienten mit metastasierenden oder chirurgisch nicht entfernbaren soliden Tumoren getestet, die nicht mit der Standardtherapie behandelt werden können. Der DuoBody®-PD-L1x4-1BB ist der erste gemeinsam entwickelte Produktkandidat, der die klinische Phase erreicht. Die Kosten und Gewinne, die im Zuge der Partnerschaft anfallen, werden im Verhältnis 50 zu 50 geteilt. Ziel der 2015 unterzeichneten und 2016 um weitere Zielstrukturen und Technologien erweiterten Zusammenarbeit ist die Entwicklung und Vermarktung mehrerer neuartiger bi-spezifischer Antikörper mit überlegener in-vivo-Wirksamkeit, die das Immunsystem spezifisch gegen Krebszellen aktivieren.

Im September 2019 hat BioNTech eine Partnerschaft mit der Bill & Melinda Gates Stiftung für die Entwicklung von HIV- und Tuberkulose Impfstoffen bekanntgegeben. Im Rahmen dieser Vereinbarung hat BioNTech im September 2019 eine erste Kapitalinvestition in Höhe von 49.864 T€ (55.000 T\$) erhalten. Die Finanzierung dient der Entwicklung von präklinischen Impfstoffen sowie Immuntherapiekandidaten für HIV- und Tuberkulose Infektionen, die präventiv eingesetzt werden und im Fall von HIV eine dauerhafte Remission ohne antiretrovirale Therapie ermöglichen sollen. Durch zusätzliche zukünftige Finanzierungsverein-

barungen könnten sich die Gesamtinvestitionen der Gates Stiftung auf bis zu 100.000 T\$. belaufen. In diesem Fall wird dieses Kapital für die klinische Entwicklung von Produktkandidaten sowie der Initiierung neuer Projekte in diesem Indikationsbereich verwendet werden.

### Finanzierung

#### KAPITALERHÖHUNG SERIES B

Im Juni und August 2019 hat BioNTech die Series-B-Finanzierungsrunde abgeschlossen, um seine individualisierte Krebsmedizinpipeline weiterzuentwickeln. Hierbei handelt es sich um eine der größten Einzelfinanzierungen eines privaten europäischen Biotechnologieunternehmens. In diesem Zusammenhang gab BioNTech insgesamt 12.465.288 Stammaktien (mit Ausnahme von 5.524.506 Stammaktien, die an einen in Hongkong ansässigen Investor ausgegeben und anschließend aufgrund keiner Gegenleistung wieder an BioNTech übertragen wurden; diese Aktien werden als eigene Anteile gehalten) an neue sowie bestehende Aktionäre zu einem Preis von 18,10 \$ pro Aktie für einen Gesamterlös von 198.548 T€ (225.622 T\$) aus. Die Kapitalerhöhung erhöhte das gezeichnete Kapital um 17.990 T€ und die Kapitalrücklage um 186.390 T€ sowie die Erfassung von eigenen Anteilen in Höhe von 5.525 T€.

#### BÖRSENGANG („INITIAL PUBLIC OFFERING – IPO“)

Am 10. Oktober 2019 erhöhte BioNTech in Verbindung mit dem Börsengang das gezeichnete Kapital um 10.000 T€. American Depositary Shares (ADS), die Stammaktien repräsentieren, wurden an der Nasdaq Global Select Market zu einem Preis von 15,00 \$ angeboten. Am 6. November 2019 erhöhte BioNTech das gezeichnete Kapital um weitere 517 T€ durch die Ausübung der im Zusammenhang mit dem

Die nachstehende Tabelle gibt eine Übersicht zu 2019 und 2018 an Vorstandsmitglieder ausgegebenen Aktienoptionen, die in den Geschäftsjahren 2019 und 2018 an Vorstandsmitglieder ausgegeben wurden.

	Zeitpunkt der Ausgabe <sup>1</sup>	Anzahl der den Aktienoptionen zugrunde liegenden Stammaktien <sup>4</sup>	Ausübungspreis (€)	Ablauf der Möglichkeit zur Optionsausübung
Prof. Dr. Ugur Sahin	15.11.2018	1.830.348	10,14	17.9.2026
	10.10.2019 <sup>2</sup>	4.374.963	13,60	11.10.2029
Sean Marett	15.11.2018	610.110	10,14	17.9.2026
Dr. Sierk Poetting	15.11.2018	610.110	10,14	17.9.2026
Dr. med. Özlem Türeci	15.11.2018 <sup>3</sup>	1.952.334	10,14	17.9.2026

<sup>1</sup> Wenn nicht anders angegeben, werden alle Optionen am 16. September 2022 unverfallbar.

<sup>2</sup> Die Option wird jährlich in gleichen Raten nach vier Jahren, jeweils am 10. Oktober in den Jahren 2020, 2021, 2022 und 2023, unverfallbar.

<sup>3</sup> Die Optionen wurden am 16. März 2019 unverfallbar, gleichwohl kann die Ausübung erst ab dem 16. September 2022 erfolgen.


<sup>4</sup> Die Anzahl der Stammaktien bildet den Effekt der Kapitalerhöhung aufgrund eines Aktiensplits von 1:18 ab, der am 8. September 2019 mit der Eintragung im Handelsregister wirksam wurde.

# Link Analysis










# CARB-X




GIZ




Bill & Melinda Gates Foundation

Mitglied

Financed \$6.150.971 Finance F... Bill & Melinda Gates Foundation




## WGHA - Washington Global Health Alliance



Almost all of these individuals' employers receive donations from the Gates Foundation.




# MMV







# Adjuvant Capital




# Merck




# Merck + Jule Louise Gerberding (direct connections)







# Johnson & Johnson




# IVI - International Vaccine Institute




# ID2020









# ONE




# IFPMA - International Federation of Pharmaceutical Manufacturers & Associations




# PharmAccess Foundation







# CGD - Center for Global Development



# NTI - Nuclear Threat Initiative (1 Level)



# NTI - Nuclear Threat Initiative + Direct Linked Persons (1 Level)



## **NTI - Nuclear Threat Initiative (Additional Information)**

<https://www.nti.org/newsroom/news/nti-bio-focuses-high-consequence-deliberate-and-global-catastrophic-biological-risks-during-world-health-assembly-side-event/>

<https://www.nti.org/about/projects/fostering-biosecurity-innovation-and-risk-reduction/biosecurity-innovation-and-risk-reduction-initiative-launch/>

[https://media.nti.org/documents/Biosecurity\\_Innovation\\_and\\_Risk\\_Reduction.pdf](https://media.nti.org/documents/Biosecurity_Innovation_and_Risk_Reduction.pdf)


[https://media.nti.org/documents/NTI\\_BIO\\_TTX\\_RPT\\_FINAL.pdf](https://media.nti.org/documents/NTI_BIO_TTX_RPT_FINAL.pdf)

[https://media.nti.org/documents/NTI\\_Paper\\_A\\_Spreading\\_Plague\\_FINAL\\_061119.pdf](https://media.nti.org/documents/NTI_Paper_A_Spreading_Plague_FINAL_061119.pdf)


[https://media.nti.org/documents/Participants\\_List\\_TTX\\_on\\_Deliberate\\_Bio\\_Event\\_2019\\_MSC\\_2.14\\_FINAL.pdf](https://media.nti.org/documents/Participants_List_TTX_on_Deliberate_Bio_Event_2019_MSC_2.14_FINAL.pdf)




# CSIS - Center for Strategic and International Studies / Strengthening America's Health Security




# CSIS - Center for Strategic and International Studies / Strengthening America's Health Security




# GVP - Global Virome Project - 1 Level Connections




## GVP - Global Virome Project (Level 2 Connections)




# METABIOTA (Level 2 Connections)




# IHME - The Institute for Health Metrics and Evaluation



# IHME - The Institute for Health Metrics and Evaluation incl. direct connections of Members



# DARPA



Pentagon tasks Pfizer with radically rethinking vaccine development - <https://www.fiercepharma.com/r-d/pentagon-tasks-pfizer-radically-rethinking-vaccine-development> (2013-12-09)


BARDA - Rapidly advancing a Zika mRNA vaccine / DARPA – Advancing mRNA therapies and vaccines for biodefense

- <https://www.modernatx.com/ecosystem/strategic-collaborators/mrna-strategic-collaborators-government-organizations> (09/2016 & 10/2013)



# Selected Views

Peter Piot  
Lothar Wieler  
Victor Dzau  
Georg F Gao  
Jeremy Farrar  
Christian Drosten  
Ralph S. Baric  
Peter Daszak



# CDC - 1 Level



CDC - Centers for Disease Contr...


Funding Partners

Donor




Patent - US7220852B1 - Coronavi...

# CDC - Director / Former Director - 1 Level



# Contributors of selected documents



1 - Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19 <https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2930418-9>


2 - Leopoldina-Stellungnahmen zur Coronavirus-Pandemie (2020) <https://www.leopoldina.org/publikationen/detailsicht/publication/leopoldina-stellungnahmen-zur-coronavirus-pandemie-2020/>

3 - Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, 17 January 2020 <https://apps.who.int/iris/rest/bitstreams/1266309/retrieve>


4 - Document - The Global Virome Project [https://www.who.int/bulletin/online\\_first/BLT.17.205005.pdf](https://www.who.int/bulletin/online_first/BLT.17.205005.pdf)

5 - Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR (2020-01-13) [https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88\\_2](https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2)


# The Global Virome Project



# The Global Virome Project




## Peter Piot & Heidi Larson - additional links







# Ralph S. Baric - 1 Level




# Ralph S. Baric - 2 Level



# Selected Persons - Event Atlantic Storm / Clade-X / Event 201 / Dark Winter




# YGL - Young Global Leaders - 1 Level






# YGL Members and their direct connection to existing objects.




# Tara O'Toole and In-Q-Tel




IT



# Google




# Facebook




“EXERCISES”


# Dark Winter (2001)



# Atlantic Storm (2005)




# Clade-X (2018)



[https://www.centerforhealthsecurity.org/our-work/events/2018\\_clade\\_x\\_exercise/](https://www.centerforhealthsecurity.org/our-work/events/2018_clade_x_exercise/)  
<https://www.weforum.org/agenda/2018/07/infectious-disease-pandemic-clade-x-johns-hopkins/>



# NTI - 2018-07-20/21 - Constructive discussion during the June 20-21, 2018 Meeting on biological risk hosted by the Wellcome Trust, NTI, and the World Economic Forum in London




List of participants not available...

<https://www.nti.org/newsroom/news/nti-bio-partners-wellcome-trust-and-world-economic-forum-host-meeting-biosecurity-innovation-and-risk-reduction/>




# NTI - 2018-10-29 - Biosecurity Innovation and Risk Reduction Initiative Launch



- <https://www.nti.org/about/projects/fostering-biosecurity-innovation-and-risk-reduction/>
- [https://media.nti.org/documents/Biosecurity Innovation and Risk Reduction.pdf](https://media.nti.org/documents/Biosecurity%20Innovation%20and%20Risk%20Reduction.pdf)
- [https://media.nti.org/documents/Initiative Participants and Initiative Members List October 29 Kickoff.pdf](https://media.nti.org/documents/Initiative%20Participants%20and%20Initiative%20Members%20List%20October%2029%20Kickoff.pdf)
- [https://media.nti.org/documents/NTI Paper 5 Establishing a Seal of Approval to Incentivize Adherence to Biosec a5iL1rO.pdf](https://media.nti.org/documents/NTI%20Paper%205%20Establishing%20a%20Seal%20of%20Approval%20to%20Incentivize%20Adherence%20to%20Biosec%20a5iL1rO.pdf)

- [https://media.nti.org/documents/NTI Initiative - Paper 2 - Instituting Biosecurity Investment.pdf](https://media.nti.org/documents/NTI%20Initiative%20-%20Paper%202%20-%20Instituting%20Biosecurity%20Investment.pdf)
- [https://media.nti.org/documents/NTI Initiative - Paper 6 - Additional Topics for Potential Discussion.pdf](https://media.nti.org/documents/NTI%20Initiative%20-%20Paper%206%20-%20Additional%20Topics%20for%20Potential%20Discussion.pdf)
- [https://media.nti.org/documents/NTI Initiative - 3 - Standards for Fundors and Grantees to Identify.pdf](https://media.nti.org/documents/NTI%20Initiative%20-%203%20-%20Standards%20for%20Fundors%20and%20Grantees%20to%20Identify.pdf)
- [https://media.nti.org/documents/NTI Initiative - Paper 4 - Insurance Incentives for Reducing Biological Risks.pdf](https://media.nti.org/documents/NTI%20Initiative%20-%20Paper%204%20-%20Insurance%20Incentives%20for%20Reducing%20Biological%20Risks.pdf)
- [https://media.nti.org/documents/NTI Initiative - Paper 1 - Universal Platform to Prevent Illicit Gene Synthesi zVnWfjM.pdf](https://media.nti.org/documents/NTI%20Initiative%20-%20Paper%201%20-%20Universal%20Platform%20to%20Prevent%20Illicit%20Gene%20Synthesi%20zVnWfjM.pdf)

# NTI - 2019-02-14 - Tabletop Exercise on International Response to Deliberate Biological Events Munich Security Conference




[https://media.nti.org/documents/NTI\\_BIO\\_TTX\\_RPT\\_FINAL.pdf](https://media.nti.org/documents/NTI_BIO_TTX_RPT_FINAL.pdf)

[https://media.nti.org/documents/NTI\\_Paper\\_A\\_Spreading\\_Plague\\_FINAL\\_061119.pdf](https://media.nti.org/documents/NTI_Paper_A_Spreading_Plague_FINAL_061119.pdf)


[https://media.nti.org/documents/Participants\\_List\\_TTX\\_on\\_Deliberate\\_Bio\\_Event\\_2019\\_MSC\\_2.14\\_FINAL.pdf](https://media.nti.org/documents/Participants_List_TTX_on_Deliberate_Bio_Event_2019_MSC_2.14_FINAL.pdf)

# NTI - 2019-05-29 - bio Focuses on High-Consequence, Deliberate, and Global Catastrophic Biological Risks During World Health Assembly Side Event



<https://www.nti.org/newsroom/news/nti-bio-focuses-high-consequence-deliberate-and-global-catastrophic-biological-risks-during-world-health-assembly-side-event/>

# NTI - 2019-12-xx - Washington, DC Tabletop Exercise Participants




# NTI - 2020-02-xx - 2020 Munich Security Conference Tabletop Exercise Participants



# Wilton Park - 2018-11-07/8/9 - Powerful actor, high impact bio-threats



# Munich Security Conference / Sicherheitskonferenz München









“Meetings”

Public Congress on Global Health for  
CDU/CSU Parliamentary Group  
2019-05-08




# 2021-01-12/32 Some Future forum on Preparednes (SCHMIDT FUTURES)




“Gang”


# BMGF Scientific Advisory Committee




## Commission's advisory panel on COVID-19 (E03719)



# Eurosurveillance editorial board (2 Level)




# International Advisory Board on Global Health







# NTI - Expert Contributors to Scenario Development




# RKI Robert Koch Institut - Scientific Advisory Board for the Centre for International Health Protection (ZIG)



# Connections between Georg F. Gao (Chinese CDC), Chris Elias (Gates Foundation), Christian Drosten (Charite), Lothar Wieler (Robert Koch Institut), Jeremy Farrar (Wellcome Trust)



Connections between Lothar Wieler (Robert Koch Institut), Jeremy Farrar (Wellcome Trust), Joachim Sauer (Leopoldina), Georg F. Gao (Chinese CDC), Peter Piot (Commissions Adivsory Panel, Gates Foundation Senior Fellow), Christian Drosten (Charite), Chris Elias (Gates Foundation), Ilona Kickbusch, Hans-Ulrich Holtherm (BGM)



Commission’s advisory panel on COVID-19 (E03719)  
<https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupId=3719&fromMeetings=true&meetingId=20410>

NTI - 2019-02-14 - Tabletop Exercise on International Response to Deliberate Biological Events  
 Munich Security Conference

International Advisory Board on Global Health  
<https://www.bundesgesundheitsministerium.de/english-version/press/international-advisory-board.html>

CDU / CSU - Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen  
<https://www.cducsu.de/veranstaltungen/globale-gesundheit-st-rken-un-nachhaltigkeitsziel-umsetzen/referenten>

# Sample of Public Private Partnership

Open Letter to Biden Administration – 3<sup>rd</sup> August 2021

“US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security”

[https://healthpolicy.duke.edu/sites/default/files/2021-08/USEPCR%20Cover%20letter\\_FINAL\\_For%20Distribution.pdf](https://healthpolicy.duke.edu/sites/default/files/2021-08/USEPCR%20Cover%20letter_FINAL_For%20Distribution.pdf)

## US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security

---

We are at an exceedingly perilous and urgent moment in the COVID-19 pandemic. The Delta variant, vastly more dangerous and pernicious than the original SARS-CoV-2 virus, has rapidly spread worldwide. It has been driving a deadly summer surge in the US; ripping through Latin America; causing Indonesia to become the next Asian hotspot; and fueling a third wave of the pandemic in Africa, where less than two percent of the population has been [fully vaccinated](#).

To respond, the US must build on the rapid development and availability of its highly effective vaccines – ensuring easy access for any American who wants to be vaccinated, and readiness to rapidly deploy boosters and vaccines for children. But as Delta has shown, an effective domestic response is not enough.

We are in a global war against a virus that doesn't respect borders and rapidly advances across continents. If the virus continues to circulate largely unchecked in many parts of the world, there is a very real prospect of new variants emerging that could totally pierce vaccine immunity, returning America and the rest of the world to square one.

The only way to prevent such a catastrophe is to dramatically decrease cases and slow transmission of the virus through widespread global vaccination, combined with other public health measures. Inequitable access to high-quality vaccines threatens to prolong the pandemic and destabilize economies and societies around the world.

To [date](#), 82 percent of all COVID-19 vaccine doses that have gone into arms worldwide have been administered in high- and upper middle-income countries. By contrast, less than one percent have been administered in low-income countries. Meanwhile, COVAX, the multinational vaccine facility, is struggling to meet this challenge, having [distributed](#) only 153 million doses out of 4.1 billion administered [worldwide](#).

We are facing the very real possibility that low- and lower-middle income countries will be stuck at low vaccine coverage levels through 2022 and beyond, an outcome that will be deadly. The deep divide between vaccine haves and have-nots is a challenge to our conscience and a major threat to our economic recovery and national security.

Fortunately, the supply of high-quality vaccines produced by US and allied manufacturers is [projected](#) to exceed 7 billion doses in 2021 and 14 billion doses in 2022 – more than enough to protect Americans and vaccinate the world. But doing so will require coordinated action by the US, other nations, and manufacturers to finance, allocate, and deliver doses where they are most acutely needed.

The US is on track to have over 1 billion excess doses, even assuming vaccinations and boosters for the entire population. This means we can combat the Delta-driven surge at home, while at the same time donating doses to combat it abroad. Indeed, we can – and must – do both simultaneously. This world war requires a global plan of attack.

The US and G7 allies have taken important but modest steps to close the global vaccine gap, including by accelerating large-scale production and delivery of high-quality vaccines, increasing financial support to COVAX, and committing to share roughly 900 million doses over the next year (including 580 million from the US). But these actions fall far short of the true scale and urgency required.

Much more needs to be done to provide high-quality vaccines more quickly, and to build countries' vaccine distribution and delivery capacity, which is rapidly becoming the key constraint in the race between vaccines and variants.

With the global situation becoming more dire, and current global efforts proving to be woefully insufficient, urgent US leadership is needed to get doses into arms, galvanize global action, and protect our national security. That is why **we call on President Biden to:**

- **Host a presidential-level “Global Vaccination Summit”** before the UN General Assembly meeting in September; the Summit should bring together public and private sector leaders from around the world, especially from low- and lower-middle income countries, and secure commitments to take the needed actions to close vaccine supply gaps and address financing and capacity gaps in vaccine distribution, delivery, and demand generation;
- **Rally global leaders to commit before or at the Summit to meeting the goal of vaccinating 70 percent of the world's population by mid-2022;** and
- **Launch a US Emergency Plan for Global COVID-19 Relief to help achieve that goal** and augment multilateral efforts, including the COVAX/WHO-coordinated global response and regionally-led efforts such as [the Africa Vaccine Acquisition Task Team \(AVATT\)](#).

The US Emergency Plan for Global COVID-19 Relief should be White House-led, spearheaded by a Global COVID-19 Emergency Response Coordinator reporting to the President and supported by a special inter-agency task force. Its main objectives should be to:

- **Strengthen global coordination of vaccine supply chains and manufacturing.** Greater transparency and accountability in the vaccine marketplace are [essential](#). The US should press for the development of comprehensive monthly estimates of global vaccine input availability (e.g., bioreactors, lipids, filters) and vaccine supply for the coming 12-18 months, so that the US and other countries will have assurances of sufficient doses for future domestic needs, while also maximizing the amount of high-quality vaccines available for global use;
- **Increase US donations to at least 1 billion doses by mid-2022**, including 500 million in 2021, and push other high-income countries to substantially increase donations, so that the US and G7/EU allies collectively donate 1-2 billion doses by the end of 2021;
- **Accelerate globally distributed manufacturing capacity for vaccines and vaccine inputs** by providing financial and technical assistance, and facilitating private sector licensing and knowledge transfer, including for mRNA platform vaccines, to ramp up vaccine manufacturing capabilities in Africa, Latin America, and Asia; and by reaching a global agreement on reducing the use of export restrictions for COVID-19 vaccines, therapeutics, diagnostics, and related inputs; and
- **Most critically, ensure that doses are translated into vaccinations, and strengthen health systems and preparedness for future pandemics**, by accelerating a US-led effort to increase vaccine distribution and delivery capacity, and increase vaccine confidence and demand, in countries with the highest burden of disease, lowest vaccination rates, and least resources, augmenting and complementing multilateral efforts by the development banks, Access to COVID-19 Tools Accelerator and COVAX, Africa Centers for Disease Control, and others.

While these steps can and should be implemented now, they would benefit from additional Congressional support. The administration and Congress should urgently work to advance legislation to fund and sustain a comprehensive international COVID-19 response as well as health systems strengthening and pandemic preparedness efforts.

This plan should be implemented to serve as a catalyst and model for efforts by other high-income nations to use their excess vaccine supplies and technical capabilities to augment the global response. In addition, while focused on the present crisis, this plan should evolve to become part of a permanent initiative to increase preparedness for future pandemics.

This US Emergency Plan for Global COVID-19 Relief reflects both our ideals as a people and our interests as a nation. By galvanizing global efforts to vaccinate the population of the world's poorest, most afflicted countries, it will accelerate the end of the pandemic – here and everywhere.

Please read the full report, [US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security](#), to learn more.

### Signed By



**Amanda Glassman**  
Executive Vice President,  
Center for Global  
Development; CEO of CGD  
Europe; and Senior Fellow

**Rachel Silverman**  
Policy Fellow, Center for  
Global Development

**Prashant Yadav**  
Senior Fellow, Center for  
Global Development

**J. Stephen Morrison**  
Senior Vice President and  
Director, Global Health Policy  
Center, CSIS

**Katherine Bliss**  
Senior Fellow, Global Health  
Policy Center, CSIS

**Anna McCaffrey**  
Fellow, Global Health Policy  
Center, CSIS

**Gary Edson**  
President, COVID  
Collaborative

**John Bridgeland**  
CEO, COVID Collaborative

**Anjali Balakrishna**  
Program Director, COVID  
Collaborative

**Mark McClellan**  
Director, Duke-Margolis  
Center for Health Policy,  
Duke University

**Krishna Udayakumar**  
Director, Duke Global Health  
Innovation Center, Duke  
University

**Michael Merson**  
Wolfgang Joklik Professor of  
Global Health, Duke Global  
Health Institute, Duke  
University

### Endorsed By

**Thomas Bollyky**  
Senior Fellow, Council on  
Foreign Relations

**Scott Gottlieb**  
Resident Fellow, American  
Enterprise Institute, and  
former Commissioner of the  
US Food and Drug  
Administration

**Carolyn Reynolds**  
Co-Founder, Pandemic  
Action Network, and Senior  
Associate, Global Health  
Policy Center, CSIS

**William Frist**  
Former U.S. Senator (R-TN)  
and Former Senate Majority  
Leader

**Margaret (Peggy)  
Hamburg**  
Former Commissioner of the  
US Food and Drug  
Administration, former  
Foreign Secretary of the  
National Academy of  
Medicine

**Helene Gayle**  
President and Chief Executive  
Officer, The Chicago  
Community Trust

**Amb [ret] Jimmy Kolker**  
Former Assistant Secretary,  
Global Affairs, Department of  
Health and Human Services


**Bruce Gellin**  
Chief, Global Public Health  
Strategy, The Rockefeller  
Foundation

**Jack Leslie**  
Chairman, Weber Shandwick

Following People/NGOs were part of open letter to Biden Administration, 3<sup>rd</sup> August 2021

Signed by / endorsed by (amongst others): Margret A. (Peggy) Hamburg, Bruce Gellin, Scott Gottlieb, Thomas Bollyky


“US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security”





# Following People/NGOs were part of open letter to Biden Administration, 3<sup>rd</sup> August 2021


Signed by / endorsed by (amongst others): Margret A. (Peggy) Hamburg, Bruce Gellin, Scott Gottlieb, Thomas Bollyky  
Extended by their relations to Gates Foundation, Wellcome Trust and others.






	A	B	C	D	E	F	G	H	I	J	K	L	M	N
1														
2														
3	<b>Sum of Grants</b>	<b>Amount</b>	<b>Total</b>	<b>Column Labels</b>										
4	<b>Row Labels</b>	<b>2010</b>	<b>2011</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>Grand Total</b>
5	<b>Albert B. Sabin Vaccine Institute</b>	<b>7.897.985</b>	<b>12.085.497</b>	<b>6.071.478</b>		<b>18.636.252</b>	<b>20.000</b>	<b>20.000</b>	<b>3.163.373</b>	<b>7.435.542</b>	<b>641.879</b>	<b>1.166.367</b>	<b>390.000</b>	<b>57.528.373</b>
6	Bill & Melinda Gates Foundation	7.897.985	12.085.497	6.071.478		18.636.252	20.000	20.000	3.163.373	7.435.542	641.879	673.577	390.000	57.035.583
7	GSK											352.600		352.600
8	Wellcome Trust											140.190		140.190
9	<b>American Enterprise Institute</b>		<b>475.536</b>	<b>1.262.124</b>		<b>1.316.217</b>	<b>159.335</b>	<b>1.157.579</b>			<b>900.000</b>	<b>250.000</b>		<b>5.520.791</b>
10	Bill & Melinda Gates Foundation		445.496	1.068.788		1.316.217	159.335	1.157.579			900.000	250.000		5.297.415
11	Robert Wood Johnson Foundation		30.040	193.336										223.376
12	<b>Center for Global Development</b>		<b>5.763.186</b>		<b>5.498.167</b>	<b>2.098.745</b>	<b>3.503.659</b>	<b>7.343.503</b>	<b>7.987.488</b>	<b>21.429.999</b>	<b>5.322.972</b>	<b>10.215.198</b>	<b>146.002</b>	<b>69.308.919</b>
13	Bill & Melinda Gates Foundation		5.763.186		5.148.167	914.025	3.503.659	4.343.503	6.187.488	21.380.057	1.164.534	8.415.198		56.819.817
14	Open Philanthropy				350.000	1.184.720		3.000.000	1.800.000	49.942	4.158.438	1.800.000		12.343.100
15	Wellcome Trust												146.002	146.002
16	<b>Center for Strategic and International Studies</b>		<b>8.145.677</b>		<b>1.000.000</b>		<b>9.537.181</b>		<b>8.074.000</b>			<b>3.761.211</b>		<b>30.518.069</b>
17	Bill & Melinda Gates Foundation		8.145.677		1.000.000		9.537.181		8.074.000			3.398.855		30.155.713
18	Open Philanthropy											118.307		118.307
19	Robert Wood Johnson Foundation											244.049		244.049
20	<b>Charité - Universitätsmedizin Berlin</b>									<b>549.999</b>	<b>1.086.181</b>	<b>259.550</b>		<b>1.895.730</b>
21	Bill & Melinda Gates Foundation									549.999	86.181	249.550		885.730
22	Wellcome Trust										1.000.000	10.000		1.010.000
23	<b>Chatham House</b>		<b>191.935</b>		<b>282.631</b>	<b>1.095.403</b>	<b>356.938</b>	<b>146.617</b>	<b>136.700</b>	<b>434.118</b>	<b>116.569</b>			<b>2.760.911</b>
24	Bill & Melinda Gates Foundation		191.935		282.631	1.095.403	307.288	146.617	136.700	434.118	116.569			2.711.261
25	Wellcome Trust						49.650							49.650
26	<b>Coalition for Epidemic Preparedness Innovations (CEPI)</b>							<b>183.362</b>	<b>101.277.016</b>	<b>80.680.175</b>	<b>4.059.969</b>	<b>20.000.000</b>		<b>206.200.522</b>
27	Bill & Melinda Gates Foundation								100.000.000			20.000.000		120.000.000
28	Wellcome Trust							183.362	1.277.016	80.680.175	4.059.969			86.200.522
29	<b>Council on Foreign Relations</b>		<b>530.000</b>	<b>400.000</b>		<b>53.100</b>		<b>1.000.000</b>			<b>183.197</b>	<b>700.294</b>	<b>698.403</b>	<b>3.564.994</b>
30	Bill & Melinda Gates Foundation		530.000	400.000				1.000.000			183.197	700.294	698.403	3.511.894
31	Robert Wood Johnson Foundation					53.100								53.100
32	<b>European Commission</b>							<b>500.000</b>			<b>45.178.000</b>	<b>500.000</b>		<b>46.178.000</b>
33	Bill & Melinda Gates Foundation							500.000			45.178.000	500.000		46.178.000
34	<b>London School of Hygiene &amp; Tropical Medicine</b>	<b>32.242.822</b>	<b>35.296.421</b>	<b>18.183.902</b>	<b>28.592.802</b>	<b>23.075.855</b>	<b>34.897.169</b>	<b>28.408.827</b>	<b>68.092.466</b>	<b>32.161.719</b>	<b>21.726.570</b>	<b>21.000.078</b>	<b>9.823.615</b>	<b>353.502.246</b>
35	Bill & Melinda Gates Foundation	21.601.425	18.672.120	1.836.336	13.123.576	10.448.820	22.056.301	14.478.175	39.982.036	19.408.074	16.359.406	7.362.722		185.328.991
36	Wellcome Trust	10.641.397	16.624.301	16.347.566	15.469.226	12.627.035	12.840.868	13.930.652	28.110.430	12.753.645	5.367.164	13.637.356	9.823.615	168.173.255
37	<b>Nuclear Threat Initiative</b>								<b>6.726.859</b>	<b>5.461.715</b>		<b>9.500.045</b>		<b>21.688.619</b>
38	Bill & Melinda Gates Foundation								250.000			1.000.045		1.250.045
39	Open Philanthropy								6.476.859	5.461.715		8.500.000		20.438.574
40	<b>Pfizer</b>			<b>96.462</b>				<b>17.252.854</b>						<b>17.349.316</b>
41	Bill & Melinda Gates Foundation							17.252.854						17.252.854
42	Wellcome Trust			96.462										96.462
43	<b>Robert Koch Institut</b>									<b>38.317</b>		<b>253.000</b>		<b>291.317</b>
44	Bill & Melinda Gates Foundation											253.000		253.000
45	Wellcome Trust									38.317				38.317
46	<b>World Health Organization</b>	<b>44.012.053</b>	<b>72.270.654</b>	<b>200.885.383</b>	<b>399.386.075</b>	<b>645.774.522</b>	<b>197.178.706</b>	<b>118.061.247</b>	<b>234.127.556</b>	<b>284.599.026</b>	<b>217.274.610</b>	<b>298.952.191</b>	<b>112.880.895</b>	<b>2.825.402.918</b>
47	Bill & Melinda Gates Foundation	44.012.053	71.993.007	200.885.383	399.366.566	642.616.767	195.112.242	117.048.753	234.086.580	277.644.327	213.837.542	296.027.811	99.743.257	2.792.374.288
48	Robert Wood Johnson Foundation							448.830		429.829	451.543			1.330.202
49	Wellcome Trust		277.647		19.509	3.157.755	2.066.464	563.664	40.976	6.524.870	2.985.525	2.924.380	13.137.638	31.698.428
50	<b>Grand Total</b>	<b>84.152.860</b>	<b>134.758.906</b>	<b>226.899.349</b>	<b>434.759.675</b>	<b>692.050.094</b>	<b>245.652.988</b>	<b>174.073.989</b>	<b>429.623.775</b>	<b>432.752.293</b>	<b>296.742.947</b>	<b>366.304.934</b>	<b>123.938.915</b>	<b>3.641.710.725</b>


# Media



# Luminate + Child Objects 1 Level connection



<https://firstdraftnews.org>



Misc





BanQu Inc.  
Investor of Change.org



[BanQu Inc. :: Minnesota \(US\) :: OpenCorporates](#)

### BanQu Inc. BRANCH

**Company Number** a372c8f0-1fd4-e511-8164-00155d01c56d  
**Native Company Number** 873011800028  
**Status** Active  
**Incorporation Date** 15 February 2016 (over 5 years ago)  
**Company Type** Business Corporation (Foreign)  
**Jurisdiction** [Minnesota \(US\)](#)  
**Branch** Branch of [BANQU, INC.](#) (Delaware (US))  
**Registered Address** 1010 Dale St N  
 St Paul  
 55117-5603  
 MN  
 USA  
**Governing Legislation** 303  
**Agent Name** National Registered Agents, Inc

### Change.org

### Abbott Diabetes Care Sales Corporation

BRANCH

**Company Number** b96428df-8dd4-e011-a886-001ec94ffe7f  
**Native Company Number** 1899138-3 [Abbott Diabetes Care Sales Corporation :: Minnesota \(US\) :: OpenCorporates](#)  
**Status** Active  
**Incorporation Date** 16 June 2006 (almost 15 years ago)  
**Company Type** Business Corporation (Foreign)  
**Jurisdiction** [Minnesota \(US\)](#)  
**Branch** Branch of [ABBOTT DIABETES CARE SALES CORPORATION](#) (Delaware (US))  
**Registered Address** 1010 Dale St N  
 St Paul  
 55117-5603  
 MN  
 USA  
**Governing Legislation** 303  
**Agent Name** C T Corporation System Inc  
**Directors / Officers** C T Corporation System Inc, agent  
 Jared Watkin, chief executive officer  
**Registry Page** <https://mbisportal.sos.state.mn.us/Bu...>


[Company officers with names matching 'C T Corporation System Inc' :: Page 1 :: OpenCorporates](#)



[642 Simon Ave - Google Maps](#)

C T Coporation has several hundred branches of various companies registered here. Interesting: There are some pharmaceutical companies registered here. C T Corporation is a part of Walter Kluwer Group.


## ROADMAP FOR THE IMPLEMENTATION OF ACTIONS BY THE EUROPEAN COMMISSION BASED ON THE COMMISSION COMMUNICATION AND THE COUNCIL RECOMMENDATION ON STRENGTHENING COOPERATION AGAINST VACCINE PREVENTABLE DISEASES


ACTIONS	TIMELINES AND DELIVERABLES					
	2018	2019	2020	2021	2022	
<p>Examine the feasibility of developing a <b>common vaccination card/passport for EU citizens</b> (that takes into account potentially different national vaccination schedules and), that is compatible with electronic immunisation information systems and recognised for use across borders, without duplicating work at national level.</p> <p><b>CR 16 and CC*</b></p>		<p>Feasibility study for the development of a common EU vaccination card</p>			<p>Commission proposal for a common vaccination card/passport for EU citizens</p> 	
<p>Produce on a regular basis a <b>Report on the State of Vaccine Confidence in the EU</b>, to monitor attitudes to vaccination. Based on that report and taking into account related work by WHO, present guidance that can support Member States in countering vaccine hesitancy.</p> <p><b>CR 17 and CC</b></p>		<p>State of Vaccine Confidence in the EU 2020 Follow up of the study published in October 2018 <a href="https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_confidence_en.pdf">https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_confidence_en.pdf</a></p> <p>Guidance on countering vaccine hesitancy tailored to specific needs identified by the Member States and/or vaccine specific issues</p> <p>Special Eurobarometer - Europeans' attitudes towards vaccination <a href="https://ec.europa.eu/commfrontoffice/publicopinion/index.cfm/survey/getsurveydetail/instruments/special/surveyky/2223">https://ec.europa.eu/commfrontoffice/publicopinion/index.cfm/survey/getsurveydetail/instruments/special/surveyky/2223</a></p>				

\* Basis for action:  
CR for Council Recommendation and the number of the Recommendation in the legal text. CC for Commission Communication


“Selected Person”


# Chris (Christopher) Elias






# Margret A. Hamburg







# Scott Gottlieb







# Anthony Fauci












# Matthew Hepburn














# Emer Cooke





# Georg F. Gao






# Tim Evans







# Julie Louse Gerberding



# Peter Daszak




# Joe Cerrell







# Richard Danzig




# Beth Cameron







# Amelia Fawcett





# Muhammed Pate



# Victor Dzau









# John Nkengasong

